What is it about?
Immune checkpoint blockade has revolutionized cancer treatment, which won a Nobel prize a few years ago. We found that an immune checkpoint called PD-L1 is regulated by an oncogenic protein, which is thought to be a dead enzyme ERBB3 in cancer cells.
Featured Image
Why is it important?
This study suggests the putative dead enzyme is not really dead, and it has important functions for cancer to evade immune surveillance.
Read the Original
This page is a summary of: PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain, Genes & Diseases, July 2023, Tsinghua University Press,
DOI: 10.1016/j.gendis.2022.11.003.
You can read the full text:
Contributors
The following have contributed to this page
